{"id":"https://openalex.org/W3137323645","doi":"https://doi.org/10.1007/s13300-021-01034-w","title":"Once-Daily Oral Semaglutide Versus Injectable GLP-1 RAs in People with Type 2 Diabetes Inadequately Controlled on Basal Insulin: Systematic Review and Network Meta-analysis","display_name":"Once-Daily Oral Semaglutide Versus Injectable GLP-1 RAs in People with Type 2 Diabetes Inadequately Controlled on Basal Insulin: Systematic Review and Network Meta-analysis","alternate_titles":[],"publication_year":2021,"publication_date":"2021-03-16","ids":{"openalex":"https://openalex.org/W3137323645","doi":"https://doi.org/10.1007/s13300-021-01034-w","mag":"3137323645","pmid":"https://pubmed.ncbi.nlm.nih.gov/33723769","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/8099977"},"language":"en","primary_location":{"id":"doi:10.1007/s13300-021-01034-w","doi":"https://doi.org/10.1007/s13300-021-01034-w","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s13300-021-01034-w","pdf_url":"https://link.springer.com/content/pdf/10.1007/s13300-021-01034-w.pdf","source":{"id":"https://openalex.org/S16535137","display_name":"Diabetes Therapy","issn_l":"1869-6961","issn":["1869-6961","1869-6953"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-d","doyens","jufo-1","ki-jl-1","norway-1","oarl","poland-100","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320330","host_organization_name":"Adis, Springer Healthcare","host_organization_lineage":["https://openalex.org/P4310320330","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Adis, Springer Healthcare","Springer Nature"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes Therapy","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W3137323645"],"child_works_count":0,"type":"review","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://link.springer.com/content/pdf/10.1007/s13300-021-01034-w.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5064518045","display_name":"Barrie Chubb","orcid":"https://orcid.org/0000-0001-7271-051X","observed_orcids":["https://orcid.org/0000-0001-7271-051X"]},"institutions":[{"id":"https://openalex.org/I4210126084","display_name":"Novo Nordisk (United Kingdom)","ror":"https://ror.org/0415cr103","country_code":"GB","type":"company","lineage":["https://openalex.org/I189090001","https://openalex.org/I2801134892","https://openalex.org/I4210126084","https://openalex.org/I4210159963"]}],"countries":["GB"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Barrie Chubb","raw_affiliation_strings":["Novo Nordisk Ltd, Gatwick, UK. bach@novonordisk.com","Novo Nordisk Ltd, Gatwick, UK"],"raw_orcid":"https://orcid.org/0000-0001-7271-051X","affiliations":[{"raw_affiliation_string":"Novo Nordisk Ltd, Gatwick, UK. bach@novonordisk.com","institution_ids":["https://openalex.org/I4210126084"]},{"raw_affiliation_string":"Novo Nordisk Ltd, Gatwick, UK","institution_ids":["https://openalex.org/I4210126084"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5042089056","display_name":"Palvi Gupta","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Palvi Gupta","raw_affiliation_strings":["DRG Abacus Part of Clarivate, Bangalore, India"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"DRG Abacus Part of Clarivate, Bangalore, India","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5037568476","display_name":"Jatin Gupta","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Jatin Gupta","raw_affiliation_strings":["DRG Abacus Part of Clarivate, Gurgaon, India"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"DRG Abacus Part of Clarivate, Gurgaon, India","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5001771184","display_name":"Solomon Nuhoho","orcid":"https://orcid.org/0000-0001-7061-0101","observed_orcids":["https://orcid.org/0000-0001-7061-0101"]},"institutions":[{"id":"https://openalex.org/I189090001","display_name":"Novo Nordisk (Denmark)","ror":"https://ror.org/0435rc536","country_code":"DK","type":"company","lineage":["https://openalex.org/I189090001","https://openalex.org/I2801134892","https://openalex.org/I4210159963"]}],"countries":["DK"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Solomon Nuhoho","raw_affiliation_strings":["Novo Nordisk A/S, S\u00f8borg, Denmark"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novo Nordisk A/S, S\u00f8borg, Denmark","institution_ids":["https://openalex.org/I189090001"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068409224","display_name":"Klaus Kallenbach","orcid":"https://orcid.org/0000-0002-4451-2644","observed_orcids":["https://orcid.org/0000-0002-4451-2644"]},"institutions":[{"id":"https://openalex.org/I189090001","display_name":"Novo Nordisk (Denmark)","ror":"https://ror.org/0435rc536","country_code":"DK","type":"company","lineage":["https://openalex.org/I189090001","https://openalex.org/I2801134892","https://openalex.org/I4210159963"]}],"countries":["DK"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Klaus Kallenbach","raw_affiliation_strings":["Novo Nordisk A/S, S\u00f8borg, Denmark"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novo Nordisk A/S, S\u00f8borg, Denmark","institution_ids":["https://openalex.org/I189090001"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5028132227","display_name":"Michelle Elaine Orme","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Michelle Orme","raw_affiliation_strings":["ICERA Consulting, UK on behalf of DRG Abacus Part of Clarivate, Swindon, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"ICERA Consulting, UK on behalf of DRG Abacus Part of Clarivate, Swindon, UK","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5064518045"],"corresponding_institution_ids":["https://openalex.org/I4210126084"],"apc_list":{"value":6000,"currency":"USD","value_usd":6000},"apc_paid":{"value":6000,"currency":"USD","value_usd":6000},"fwci":0.9775,"has_fulltext":true,"cited_by_count":44,"citation_normalized_percentile":{"value":0.71668018,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":93,"max":99},"biblio":{"volume":"12","issue":"5","first_page":"1325","last_page":"1339"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10560","display_name":"Diabetes Management and Research","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12539","display_name":"Pharmacology and Obesity Treatment","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/oral-semaglutide","display_name":"oral semaglutide","score":0.9829999804496765},{"id":"https://openalex.org/keywords/glp-1-receptor-agonists","display_name":"GLP-1 receptor agonists","score":0.8650000095367432},{"id":"https://openalex.org/keywords/type-2-diabetes","display_name":"type 2 diabetes","score":0.9940000176429749},{"id":"https://openalex.org/keywords/basal-insulin","display_name":"basal insulin","score":0.7009999752044678},{"id":"https://openalex.org/keywords/hba1c","display_name":"HbA1c","score":0.906000018119812},{"id":"https://openalex.org/keywords/weight-loss","display_name":"weight loss","score":0.7459999918937683},{"id":"https://openalex.org/keywords/blood-pressure","display_name":"blood pressure","score":0.6470000147819519},{"id":"https://openalex.org/keywords/dulaglutide","display_name":"dulaglutide","score":0.8740000128746033},{"id":"https://openalex.org/keywords/exenatide","display_name":"exenatide","score":0.9959999918937683},{"id":"https://openalex.org/keywords/liraglutide","display_name":"liraglutide","score":0.9629999995231628},{"id":"https://openalex.org/keywords/lixisenatide","display_name":"lixisenatide","score":1.0},{"id":"https://openalex.org/keywords/adjunctive-therapy","display_name":"adjunctive therapy","score":0.7200000286102295},{"id":"https://openalex.org/keywords/glycemic-control","display_name":"glycemic control","score":0.7279999852180481}],"concepts":[{"id":"https://openalex.org/C2909862629","wikidata":"https://www.wikidata.org/wiki/Q27261089","display_name":"Semaglutide","level":5,"score":0.9824561476707458},{"id":"https://openalex.org/C2779829264","wikidata":"https://www.wikidata.org/wiki/Q21011228","display_name":"Dulaglutide","level":5,"score":0.9351298809051514},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8839696049690247},{"id":"https://openalex.org/C2781308992","wikidata":"https://www.wikidata.org/wiki/Q2526479","display_name":"Liraglutide","level":4,"score":0.7907196283340454},{"id":"https://openalex.org/C2780533449","wikidata":"https://www.wikidata.org/wiki/Q417762","display_name":"Exenatide","level":4,"score":0.7653551697731018},{"id":"https://openalex.org/C2777180221","wikidata":"https://www.wikidata.org/wiki/Q3025883","display_name":"Type 2 diabetes","level":3,"score":0.6880130767822266},{"id":"https://openalex.org/C2776442814","wikidata":"https://www.wikidata.org/wiki/Q6659956","display_name":"Lixisenatide","level":5,"score":0.6805179119110107},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5647978782653809},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.5261542201042175},{"id":"https://openalex.org/C2780580376","wikidata":"https://www.wikidata.org/wiki/Q186889","display_name":"Nausea","level":2,"score":0.42208120226860046},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.41676953434944153},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.37455320358276367},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.37438052892684937},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.28705862164497375},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.0},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.0}],"mesh":[],"locations_count":3,"locations":[{"id":"doi:10.1007/s13300-021-01034-w","doi":"https://doi.org/10.1007/s13300-021-01034-w","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s13300-021-01034-w","pdf_url":"https://link.springer.com/content/pdf/10.1007/s13300-021-01034-w.pdf","source":{"id":"https://openalex.org/S16535137","display_name":"Diabetes Therapy","issn_l":"1869-6961","issn":["1869-6961","1869-6953"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-d","doyens","jufo-1","ki-jl-1","norway-1","oarl","poland-100","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320330","host_organization_name":"Adis, Springer Healthcare","host_organization_lineage":["https://openalex.org/P4310320330","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Adis, Springer Healthcare","Springer Nature"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes Therapy","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:8099977","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC8099977/","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes Ther","raw_type":"Text"},{"id":"pmid:33723769","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/33723769","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes therapy : research, treatment and education of diabetes and related disorders","raw_type":"Journal Article"}],"best_oa_location":{"id":"doi:10.1007/s13300-021-01034-w","doi":"https://doi.org/10.1007/s13300-021-01034-w","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s13300-021-01034-w","pdf_url":"https://link.springer.com/content/pdf/10.1007/s13300-021-01034-w.pdf","source":{"id":"https://openalex.org/S16535137","display_name":"Diabetes Therapy","issn_l":"1869-6961","issn":["1869-6961","1869-6953"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-d","doyens","jufo-1","ki-jl-1","norway-1","oarl","poland-100","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320330","host_organization_name":"Adis, Springer Healthcare","host_organization_lineage":["https://openalex.org/P4310320330","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Adis, Springer Healthcare","Springer Nature"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes Therapy","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Systematic Review","id":"https://openalex.org/study-designs/systematic-review"},{"display_name":"Meta-Analysis","id":"https://openalex.org/study-designs/meta-analysis"}],"awards":[],"funders":[{"id":"https://openalex.org/F4320322436","display_name":"Novo Nordisk","ror":"https://ror.org/0435rc536"}],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W3137323645.pdf","grobid_xml":"https://content.openalex.org/works/W3137323645.grobid-xml"},"referenced_works_count":60,"referenced_works":["https://openalex.org/W580477814","https://openalex.org/W1504183466","https://openalex.org/W1505367831","https://openalex.org/W1517555081","https://openalex.org/W1524829680","https://openalex.org/W1584571461","https://openalex.org/W1598602811","https://openalex.org/W1826263849","https://openalex.org/W1924318177","https://openalex.org/W1977102586","https://openalex.org/W1986587469","https://openalex.org/W2010699829","https://openalex.org/W2037395799","https://openalex.org/W2106709036","https://openalex.org/W2106758571","https://openalex.org/W2118095379","https://openalex.org/W2122643907","https://openalex.org/W2127622911","https://openalex.org/W2135064706","https://openalex.org/W2137562839","https://openalex.org/W2137670391","https://openalex.org/W2138749579","https://openalex.org/W2165556241","https://openalex.org/W2171553260","https://openalex.org/W2193379135","https://openalex.org/W2193664952","https://openalex.org/W2276028032","https://openalex.org/W2313078525","https://openalex.org/W2415433461","https://openalex.org/W2496180703","https://openalex.org/W2561156429","https://openalex.org/W2594451671","https://openalex.org/W2598936606","https://openalex.org/W2604152120","https://openalex.org/W2695892839","https://openalex.org/W2738799702","https://openalex.org/W2757494156","https://openalex.org/W2791169690","https://openalex.org/W2801715295","https://openalex.org/W2808008353","https://openalex.org/W2809103080","https://openalex.org/W2894993577","https://openalex.org/W2915807915","https://openalex.org/W2922550132","https://openalex.org/W2945457198","https://openalex.org/W2948380809","https://openalex.org/W2948622224","https://openalex.org/W2953860251","https://openalex.org/W2974621372","https://openalex.org/W2974714926","https://openalex.org/W2979451288","https://openalex.org/W3030180492","https://openalex.org/W3114072797","https://openalex.org/W4236074123","https://openalex.org/W4240794548","https://openalex.org/W4248056555","https://openalex.org/W4254445254","https://openalex.org/W6604107555","https://openalex.org/W6659859663","https://openalex.org/W7073817871"],"related_works":["https://openalex.org/W2799276912","https://openalex.org/W2979451288","https://openalex.org/W7165679173","https://openalex.org/W2802523429","https://openalex.org/W3080787886","https://openalex.org/W4283452477","https://openalex.org/W2892305139","https://openalex.org/W3120876049","https://openalex.org/W2784318050","https://openalex.org/W4310080060"],"abstract_inverted_index":{"The":[0,116],"relative":[1],"efficacy":[2,62,297],"and":[3,63,80,89,112,151,175,181,224,227,269,271,298],"safety":[4,64],"of":[5,47,95,101,107,192,217,241,289],"once-daily":[6,193],"oral":[7,122,160,194,232,251,281,291],"semaglutide":[8,123,148,161,195,207,233,252,282],"vs.":[9,134,145,171,200,247,301],"injectable":[10,114,147,206,303],"glucagon-like":[11],"peptide-1":[12],"receptor":[13],"agonists":[14],"(GLP-1":[15],"RAs)":[16],"in":[17,50,73,190],"subjects":[18,218],"with":[19,128,166,238,293],"type":[20],"2":[21,173],"diabetes":[22],"(T2D)":[23],"inadequately":[24],"controlled":[25,45],"on":[26],"basal":[27,259],"insulin":[28],"were":[29,59,103,155,198,212],"assessed":[30],"using":[31],"network":[32],"meta-analysis":[33],"(NMA).":[34],"A":[35],"systematic":[36],"literature":[37],"review":[38],"(SLR)":[39],"was":[40,126,164,236],"performed":[41],"to":[42,141,258],"identify":[43],"randomised":[44],"trials":[46],"GLP-1":[48,304],"RAs":[49],"this":[51],"population.":[52],"Data":[53],"at":[54,275],"26":[55,276],"\u00b1":[56,277],"4":[57,278],"weeks":[58],"extracted":[60],"for":[61,67,214,265],"outcomes":[65],"feasible":[66],"the":[68,215,228,287],"NMA:":[69],"change":[70],"from":[71],"baseline":[72],"glycated":[74],"haemoglobin":[75],"(HbA":[76],"1c":[77,84,132,221,268],"),":[78],"weight":[79,169,188,270],"blood":[81],"pressure;":[82],"HbA":[83,131,220,267],"target":[85],"levels":[86],"(<":[87],"7.0%":[88,223],"\u2264":[90,225],"6.5%);":[91],"composite":[92,229],"endpoint;":[93],"incidence":[94],"nausea,":[96,243],"vomiting":[97,244],"or":[98,245,295],"diarrhoea.":[99],"Comparators":[100],"interest":[102],"all":[104,201,248],"licensed":[105],"doses":[106],"dulaglutide,":[108],"exenatide,":[109],"liraglutide,":[110],"lixisenatide":[111,176],"once-weekly":[113,146,205],"semaglutide.":[115],"NMA":[117],"included":[118],"seven":[119],"trials.":[120],"Once-daily":[121,159,231,250,280],"14":[124,162,196,234,253,283],"mg":[125,150,153,163,174,197,235,284],"associated":[127,165,237],"significantly":[129,167],"greater":[130,168],"reductions":[133,170,189],"most":[135,302],"comparators":[136,203],"(treatment":[137],"differences:":[138],"\u2212":[139,142,182],"0.42":[140],"1.32%);":[143],"differences":[144],"(0.5":[149],"1":[152,208],"doses)":[154],"not":[156],"statistically":[157],"significant.":[158],"exenatide":[172],"20":[177],"\u03bcg":[178],"(\u2212":[179],"2.21":[180],"2.39":[183],"kg":[184],"respectively);":[185],"non-statistically":[186],"significant":[187],"favour":[191],"observed":[199,213],"other":[202],"except":[204],"mg.":[209],"Similar":[210],"trends":[211],"proportion":[216],"achieving":[219],"<":[222],"6.5%":[226],"endpoint.":[230],"similar":[239,294,299],"odds":[240],"experiencing":[242],"diarrhoea":[246],"comparators.":[249],"mg,":[254],"as":[255],"an":[256,262,290],"add-on":[257],"insulin,":[260],"is":[261],"efficacious":[263],"treatment":[264,292],"reducing":[266],"meeting":[272],"glycaemic":[273],"targets":[274],"weeks.":[279],"also":[285],"offers":[286],"option":[288],"better":[296],"tolerability":[300],"RAs.":[305]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W3137323645","counts_by_year":[{"year":2026,"cited_by_count":4},{"year":2025,"cited_by_count":10},{"year":2024,"cited_by_count":13},{"year":2023,"cited_by_count":6},{"year":2022,"cited_by_count":9},{"year":2021,"cited_by_count":2}],"updated_date":"2026-11-20T13:11:24.684918","created_date":"2021-03-29T00:00:00"}
